Litcius/Paper detail

Theranostic Imaging Surrogates for Targeted Alpha Therapy: Progress in Production, Purification, and Applications

Bryce J. B. Nelson, John S. Wilson, Jan Andersson, Frank Wuest

2023Pharmaceuticals34 citationsDOIOpen Access PDF

Abstract

This article highlights recent developments of SPECT and PET diagnostic imaging surrogates for targeted alpha particle therapy (TAT) radiopharmaceuticals. It outlines the rationale for using imaging surrogates to improve diagnostic-scan accuracy and facilitate research, and the properties an imaging-surrogate candidate should possess. It evaluates the strengths and limitations of each potential imaging surrogate. Thirteen surrogates for TAT are explored: 133La, 132La, 134Ce/134La, and 226Ac for 225Ac TAT; 203Pb for 212Pb TAT; 131Ba for 223Ra and 224Ra TAT; 123I, 124I, 131I and 209At for 211At TAT; 134Ce/134La for 227Th TAT; and 155Tb and 152Tb for 149Tb TAT.

Topics & Concepts

Pet imagingSpect imagingNuclear imagingMedical physicsNuclear medicineMolecular imagingMedicinePositron emission tomographyIn vivoBiologyBiotechnologyRadiopharmaceutical Chemistry and ApplicationsRadiation Therapy and DosimetryMedical Imaging Techniques and Applications
Theranostic Imaging Surrogates for Targeted Alpha Therapy: Progress in Production, Purification, and Applications | Litcius